Stimuli-responsive nanogels for precision gut drug delivery

Overview

This solution offers a precision drug-delivery platform built on stimuli-responsive nanogels designed to release therapeutics directly at sites of gut inflammation or tissue damage. By combining a collagen-IV–targeting peptide (exposed only during vascular breach or tissue injury) with nanogels that respond to local environmental cues, the platform enables spatiotemporal delivery of a wide range of payloads, including small molecules and biologics. The offering is particularly relevant for inflammatory bowel disease, postoperative recovery, intestinal wound healing, and anti-fibrotic therapies, where localized action can improve efficacy while minimizing systemic toxicity.

Technical specifications

• Nanogel architecture: Polymeric, covalently cross-linked nanoparticles suitable for encapsulation of small molecules and macromolecular therapeutics.
• Targeting: A validated 7-amino-acid peptide ligand directed against collagen IV, enabling selective accumulation at damaged or inflamed intestinal tissue.
• Stimuli-responsive release: Multiple release handles including redox species, pH shifts, and elevated enzyme activity, allowing payload release in response to the local disease microenvironment.
• Payload flexibility: Capable of delivering diverse therapeutic cargoes, including anti-fibrotic agents and biologics such as inflammation-resolving peptides.
• In vitro validation: Established gut-on-a-chip biomicrofluidic model incorporating Caco-2 epithelial cells and lymphatic cell layers to evaluate biopharmaceutical transport.
• Preclinical validation: Demonstrated efficacy in murine models of dextran sodium sulfate colitis and postoperative anastomotic healing, including improved healing scores and weight recovery, with mechanistic support from whole-genome RNA sequencing showing suppression of pro-inflammatory signaling and a shift toward anti-inflammatory M2 macrophages.

Technology readiness level

The platform is at an advanced preclinical stage. Core nanogel chemistry, collagen-IV targeting, and stimuli-responsive release mechanisms have been developed and refined over a decade of collaborative research. Therapeutic candidates have been validated in established murine models of colitis and postoperative recovery, with demonstrated improvements in disease activity and healing outcomes. The gut-on-a-chip microfluidic model provides a translational bridge for further validation. The technology is ready for collaborative payload integration, sponsored research partnerships, and pilot studies to advance toward clinical translation.